Analysis of the main functions, effects and indications of tenofovir alafenamide fumarate tablets (Vemlidy)

Tenofovir alafenamide fumarate tablets (trade name: Vemlidy) is a new type of nucleotide reverse transcriptase inhibitor used to treat patients with chronic hepatitis B (CHB). It is the prodrug form of tenofovir, which is converted into an active drug through metabolism in the body. It can effectively inhibit the replication of hepatitis B virus (HBV), reduce liver inflammation and damage, and reduce the risk of cirrhosis and liver cancer. As a first-line anti-hepatitis B drug, tenofovir alafenamide fumarate has clinically significant antiviral efficacy and good tolerance.

First of all, tenofovir alafenamide fumarate tablets exert antiviral effects by selectively inhibiting the reverse transcriptase activity of HBV. HBVAfter infecting liver cells, reverse transcriptase is required to convert viral RNA into DNA to complete replication. After tenofovir alafenamide fumarate enters hepatocytes, it is metabolized into active tenofovir diphosphate, which can competitively bind to the active site of HBV reverse transcriptase, thereby preventing the synthesis and replication of viral DNA. This mechanism makes the drug highly effective in reducing viral load and reducing serum HBV DNA levels.

Secondly, the drug has shown good efficacy and tolerability in clinical trials. Studies have shown that in patients with chronic hepatitis B who take tenofovir alafenamide fumarate tablets for a long time, the serum HBV DNA can be significantly reduced, and an increase in the serum HBeAg serological negative conversion rate can be observed in patients who are HBeAg positive. At the same time, the drug also has a significant improvement effect on patients with abnormal liver function. It can reduce the levels of ALT and AST, reduce liver inflammatory response, and thereby protect liver cell function.

In terms of indications, tenofovir alafenamide fumarate tablets are mainly used for adult patients with chronic hepatitis B, including HBeAg positive and negative people. It can be used as the drug of choice for patients with high viral load, abnormal liver function, or risk of liver fibrosis. Compared with traditional lamivudine or adefovir, tenofovir alafenamide fumarate has higher antiviral activity and lower incidence of drug resistance. It is especially suitable for long-term management of hepatitis B patients and reduces the risk of treatment failure caused by viral mutations.

The use of tenofovir alafenamide tablets needs to be combined with the patient's specific conditions, including renal function, comorbid diseases and previous medication history. Because the drug is primarily excreted by the kidneys, patients with renal insufficiency may require dosage adjustments or extended dosing intervals. At the same time, serum HBV DNA, liver function indicators and renal function should be regularly monitored to evaluate efficacy and safety. When using this drug in combination with other antiviral drugs, you need to pay attention to potential drug interactions, but it is generally well tolerated and the adverse reactions are mostly mild to moderate, such as mild headache, nausea, or fatigue.

In general, tenofovir alafenamide fumarate tablets (Vemlidy), as a new generation of nucleotide antiviral drugs for the treatment of chronic hepatitis B, achieves efficient antiviral effects by inhibiting HBV reverse transcriptase, significantly reducing serum viral load and improving liver function indicators. It is suitable for HBeAg positive and negative chronic hepatitis B patients, especially for long-term management and patient groups who need to reduce the risk of drug resistance. Combined with good tolerability and safety, tenofovir alafenamide fumarate tablets provide a reliable, effective and long-term sustainable drug option for the clinical treatment of chronic hepatitis B.

Reference materials:https://www.drugs.com/